Anti-Human Siglec-3/CD33 Recombinant Nanobody (SAA2052) (HB185013)

Name: Anti-Human Siglec-3/CD33 Recombinant Nanobody (SAA2052)
Brand: abinScience
SKU: HB185013
Price: 191 USD
Availability: InStock

Fiche technique Partager le produit Copier les informations

Prix(USD) :

Spécification :

50ug
100ug
1mg

Nombre :

Contactez-nous

Aperçu
Images
Reférences
Fiche technique
SDS

Aperçu

Numéro de catalogue

HB185013

Marque

abinScience

Description

Anti-Human CD33 Nanobody (SAA2052) [SAA2052] (HB185013) is a alpaca monoclonal antibody detecting CD33 in ELISA, FCM. Suitable for Human and Cynomolgus.

Highlights

●Flow Cytometry — Validated for flow cytometry applications.

Reactivité des espèces

Human, Monkey

Applications

ELISA, FCM, WB

Espèce hôte

Alpaca

Clonalité

Monoclonal

Isotype

VHH-8His-Cys-tag

ID de clone

SAA2052

Applications testées

Cible

Myeloid cell surface antigen CD33, Sialic acid-binding Ig-like lectin 3, Siglec-3, CD33, gp67, SIGLEC3

Niveau d'endotoxines

Please contact with the lab for this information.

Pureté

>95% as determined by SDS-PAGE.

Purification

Purified by Nickel column.

Numéro d'accès

P20138

Forme

Liquid

Tampon de stockage

0.01M PBS pH 7.4

Reférez-vous aux informations spécifiques sur le tampon dans la copie papier du datasheet ou dans le COA spécifique au lot.

Informations d'utilisation du produit

Application	Dilution
ELISA	1:2000-1:20000
WB	1:500-1:2000

Stabilité et stockage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Contexte

Myeloid cell surface antigen CD33 is a ~39 kDa protein. Sialic-acid-binding immunoglobulin-like lectin (Siglec) that plays a role in mediating cell-cell interactions and in maintaining immune cells in a resting state. Preferentially recognizes and binds alpha-2,3- and more avidly alpha-2,6-linked sialic acid-bearing glycans. Upon engagement of ligands such as C1q or syalylated glycoproteins, two immunoreceptor tyrosine-based inhibitory motifs (ITIMs) located in CD33 cytoplasmic tail are phosphorylated by Src-like kinases such as LCK. These phosphorylations provide docking sites for the recruitment and activation of protein-tyrosine phosphatases PTPN6/SHP-1 and PTPN11/SHP-2. In turn, these phosphatases regulate downstream pathways through dephosphorylation of signaling molecules. CD33 is the therapeutic target of gemtuzumab ozogamicin (Mylotarg).

1. Vitale, C. et al. (1999) Proceedings of the National Academy of Sciences of the United States of America 96, 15091-6. PMID: 10611343

2. Vitale, C. et al. (2001) Proceedings of the National Academy of Sciences of the United States of America 98, 5764-9. PMID: 11320212

3. Lajaunias, F. et al. (2005) European journal of immunology 35, 243-51. PMID: 15597323

4. Freeman, SD. et al. (1995) Blood 85, 2005-12. PMID: 7718872

5. Paul, SP. et al. (2000) Blood 96, 483-90. PMID: 10887109

6. Son, M. et al. (2017) Scientific reports 7, 270. PMID: 28325905

7. Taylor, VC. et al. (1999) The Journal of biological chemistry 274, 11505-12. PMID: 10206955

8. Ulyanova, T. et al. (1999) European journal of immunology 29, 3440-9. PMID: 10556798

Note

For research use only.

Images

SDS-PAGE

SDS-PAGE for Anti-Human CD33 Recombinant Nanobody (SAA2052)
Bioactivity

Detects CD33 (Catalog No: HB185011) in indirect ELISA.
Western blot

Western blot analysis was performed using anti-CD33 monoclonal antibody at 1ug/mL on various samples.
Lane 1: recombinant human CD33 (Catalog No: HB185011)